Stockscreener 앱 받기
2.32
18.60%
-0.53
시간 외 거래:
2.34
0.02
+0.86%
전일 마감가:
$2.85
열려 있는:
$3.15
하루 거래량:
14.54M
Relative Volume:
6.28
시가총액:
$212.20M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.3976
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
-4.92%
1개월 성능:
+33.33%
6개월 성능:
+112.84%
1년 성능:
-41.27%
1일 변동 폭
$2.2301
$3.1599
1주일 범위
$2.2301
$3.34
52주 변동 폭
$0.9857
$5.46
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.32 | 260.68M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-02-05 | 개시 | Jefferies | Buy |
| 2023-11-29 | 개시 | William Blair | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | Stifel | Buy |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Can Cabaletta Bio Inc. stock surprise with earnings upside2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Morning Market Movers: INTS, SHPH, CARM Spark Moves - RTTNews
Cabaletta Bio stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
HC Wainwright & Co. Reiterates Buy Rating for CABA with $16 Pric - GuruFocus
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating By Investing.com - Investing.com Nigeria
Jefferies resumes coverage on Cabaletta Bio stock with Buy rating - Investing.com
Cabaletta Bio Inc. stock trendline breakdown2025 Retail Activity & Free Accurate Trade Setup Notifications - newser.com
Can Cabaletta Bio Inc. stock outperform in 2025 bull marketJuly 2025 Recap & Expert Curated Trade Ideas - newser.com
Will Cabaletta Bio Inc. benefit from macro trendsWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Cabaletta Bio's (CABA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Cabaletta Bio (CABA) Shares Surge 30% After Promising Pemphigus Vulgaris Data - GuruFocus
Cabaletta Bio, Inc. Presents First Rese-cel Data with No Pre Conditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - MarketScreener
Cabaletta Bio (CABA) Reports Positive Initial Results from RESET-PV Trial - GuruFocus
Cabaletta Bio Inc reports new data from RESET-PV trial - MarketScreener
Cabaletta Bio Reports Promising Initial Data from RESET-PV Trial of Rese-cel in Pemphigus Vulgaris Without Preconditioning - Quiver Quantitative
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress - The Manila Times
Complete B‑cell depletion in 2 of 3 PV patients — Cabaletta rese‑cel 1x10^6 cells/kg without preconditioning - Stock Titan
What the charts say about Cabaletta Bio Inc. today2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
What candlestick patterns are forming on Cabaletta Bio Inc.July 2025 Gainers & Precise Buy Zone Identification - newser.com
Published on: 2025-10-09 01:46:57 - newser.com
How to use Fibonacci retracement on Cabaletta Bio Inc.July 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Myasthenia Gravis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma - Barchart.com
Cabaletta Bio: Still Optimistic, With News Being Guided To Share Soon (CABA) - Seeking Alpha
Using fundamentals and technicals on Cabaletta Bio Inc.July 2025 Recap & Capital Efficiency Focused Ideas - newser.com
Detecting price anomalies in Cabaletta Bio Inc. with AIPortfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Published on: 2025-10-01 06:55:18 - newser.com
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Published on: 2025-09-29 01:01:46 - newser.com
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN
What analysts say about Cabaletta Bio Inc stockEarnings Beat Highlights & Outstanding Portfolio Tips - earlytimes.in
Goldman Sachs Group Inc. Trims Position in Cabaletta Bio, Inc. $CABA - MarketBeat
Volume Recap: Is Cabaletta Bio Inc. stock a top pick in earnings seasonMarket Movers & Stepwise Entry/Exit Trade Alerts - The British Mountaineering Council
Recent Uptick Might Appease Cabaletta Bio, Inc. (NASDAQ:CABA) Institutional Owners After Losing 37% Over the Past Year - 富途牛牛
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):